A Study of the Safety and Efficacy of Synvisc and Depo-Medrol in Patients With Osteoarthritis of the Hip
1 other identifier
interventional
N/A
1 country
32
Brief Summary
This is a clinical study to investigate the safety and efficacy of Synvisc and Depo-Medrol in treating patients with osteoarthritis (OA) of the hip.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
Started Nov 2003
32 active sites
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
November 1, 2003
CompletedFirst Submitted
Initial submission to the registry
August 17, 2005
CompletedFirst Posted
Study publicly available on registry
August 18, 2005
CompletedStudy Completion
Last participant's last visit for all outcomes
April 1, 2006
CompletedJuly 31, 2017
July 1, 2017
August 17, 2005
July 27, 2017
Conditions
Keywords
Outcome Measures
Primary Outcomes (1)
Pain relief
Interventions
Eligibility Criteria
You may qualify if:
- Patients with symptomatic osteoarthritis pain of hip
You may not qualify if:
- Patients with current or prior conditions or treatment that would impede measurement of efficacy and safety
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (32)
Alabama Clinical Therapeutics
Birmingham, Alabama, 35235, United States
John Higginbotham, MD Sports Medicine
Huntsville, Alabama, 35802, United States
Affiliated Orthopedic Specialists
Scottsdale, Arizona, 85260, United States
Arkansas Orthopaedic Specialists
Little Rock, Arkansas, 72205, United States
Cedars-Sinai Orthopedic Center
Los Angeles, California, 90048, United States
Jackson Arthritis Center
Oakland, California, 94609, United States
Orthopedic Medical Group
San Diego, California, 92123, United States
Orthopedic Specialists of Tamp Bay, P.A.
Clearwater, Florida, 33756, United States
Orthopedic Institute at Mercy Hospital
Miami, Florida, 33133, United States
Hughston Sports Medicine Foundation
Columbus, Georgia, 31909, United States
Idaho Arthritis & Osteoporosis Center
Meridian, Idaho, 83642, United States
Northwestern Orthopaedic Institute
Chicago, Illinois, 60611, United States
Illinois Bone and Joint Institute, Ltd.
Morton Grove, Illinois, 60053, United States
David S. Tearse, MD (Private Practice)
Cedar Rapids, Iowa, 52403, United States
Kansas City Orthopedic Institute
Leawood, Kansas, 66211, United States
Bluegrass Orthopaedics
Lexington, Kentucky, 40509, United States
Orthopedic Specialists of Louisiana
Shreveport, Louisiana, 71101, United States
Maryland General Hospital
Baltimore, Maryland, 21201, United States
Family Orthopedic Associates
Flint, Michigan, 48507, United States
Washington University School of Medicine
St Louis, Missouri, 63110, United States
UMDNJ-RWJ University Orthopedic Group
New Brunswick, New Jersey, 08901, United States
Hospital for Special Surgery
New York, New York, 10021, United States
Health Research Institute
Oklahoma City, Oklahoma, 73109, United States
Orthopedic Center for Joint Replacement & Sports Medicine
Grants Pass, Oregon, 97527, United States
Altoona Center for Clinical Research
Duncansville, Pennsylvania, 16635, United States
Lancaster Orthopedic Group
Lancaster, Pennsylvania, 17601, United States
Allegheny Orthopedic Associates
Pittsburgh, Pennsylvania, 15212, United States
Conway Medical Center
Conway, South Carolina, 29526, United States
Chattanooga Center for Sports
Chattanooga, Tennessee, 37404, United States
Gurdev Gill, MD (Private Practice)
Lubbock, Texas, 79410, United States
Carilion Bone and Joint Center, Vinton Orthopedic Surgery
Vinton, Virginia, 24179, United States
Arthritis Northwest
Seattle, Washington, 98166-2967, United States
Related Publications (1)
Spitzer AI, Bockow BI, Brander VA, Yates JW, MacCarter DK, Gudger GK, Haller S, Lake SL, Magilavy DB. Hylan G-F 20 improves hip osteoarthritis: a prospective, randomized study. Phys Sportsmed. 2010 Jun;38(2):35-47. doi: 10.3810/psm.2010.06.1781.
PMID: 20631462BACKGROUND
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Study Officials
- STUDY DIRECTOR
Medical Monitor
Genzyme, a Sanofi Company
Study Design
- Study Type
- interventional
- Phase
- phase 3
- Allocation
- RANDOMIZED
- Masking
- DOUBLE
- Purpose
- TREATMENT
- Intervention Model
- PARALLEL
- Sponsor Type
- INDUSTRY
Study Record Dates
First Submitted
August 17, 2005
First Posted
August 18, 2005
Study Start
November 1, 2003
Study Completion
April 1, 2006
Last Updated
July 31, 2017
Record last verified: 2017-07